日本高潮视频在线观看-亚洲中文字幕永不卡-精品亚洲一区二区三区-伦理片夜夜躁狠狠躁日日躁-日本最新免费不卡二区-国产精品口爆一区二区三区-av一区二区三区高清-大鸡巴疯狂抽插小穴视频-日韩中文国产在线观看免费视频

Your Good Partner in Biology Research

重組蛋白

產(chǎn)品名稱 貨號 規(guī)格
Recombinant Pongo abelii Dolichyl-diphosphooligosaccharide--protein glycosyltransferase subunit STT3A (STT3A), partial CSB-YP716178PYX
CSB-EP716178PYX
CSB-BP716178PYX
CSB-MP716178PYX
CSB-EP716178PYX-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Pongo abelii Na (+)/H (+) exchange regulatory cofactor NHE-RF3 (PDZK1), partial CSB-YP716179PYX
CSB-EP716179PYX
CSB-BP716179PYX
CSB-MP716179PYX
CSB-EP716179PYX-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Pongo abelii Solute carrier family 22 member 6 (SLC22A6), partial CSB-YP716180PYX
CSB-EP716180PYX
CSB-BP716180PYX
CSB-MP716180PYX
CSB-EP716180PYX-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Pongo abelii Uncharacterized protein C15orf52 homolog, partial CSB-YP716181PYX
CSB-EP716181PYX
CSB-BP716181PYX
CSB-MP716181PYX
CSB-EP716181PYX-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Pongo abelii Frizzled-6 (FZD6), partial CSB-YP716182PYX1
CSB-EP716182PYX1
CSB-BP716182PYX1
CSB-MP716182PYX1
CSB-EP716182PYX1-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Pongo abelii Presenilin-2 (PSEN2), partial CSB-YP716183PYX
CSB-EP716183PYX
CSB-BP716183PYX
CSB-MP716183PYX
CSB-EP716183PYX-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Pongo abelii Centrosomal protein of 68 kDa (CEP68), partial CSB-YP716184PYX
CSB-EP716184PYX
CSB-BP716184PYX
CSB-MP716184PYX
CSB-EP716184PYX-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Pongo abelii Calcineurin-like phosphoesterase domain-containing protein 1 (CPPED1) CSB-YP716185PYX
CSB-EP716185PYX
CSB-BP716185PYX
CSB-MP716185PYX
CSB-EP716185PYX-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Pongo abelii Cytochrome c oxidase subunit 6B1 (COX6B1) CSB-YP716186PYX
CSB-EP716186PYX
CSB-BP716186PYX
CSB-MP716186PYX
CSB-EP716186PYX-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Pongo pygmaeus Mediator of RNA polymerase II transcription subunit 12 (MED12), partial CSB-YP716187EXP
CSB-EP716187EXP
CSB-BP716187EXP
CSB-MP716187EXP
CSB-EP716187EXP-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Pongo abelii E3 ubiquitin-protein ligase RNF13 (RNF13), partial CSB-YP716188PYX
CSB-EP716188PYX
CSB-BP716188PYX
CSB-MP716188PYX
CSB-EP716188PYX-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Pongo abelii Serine/threonine-protein kinase Kist (UHMK1) CSB-YP716189PYX
CSB-EP716189PYX
CSB-BP716189PYX
CSB-MP716189PYX
CSB-EP716189PYX-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Pongo abelii Protein LBH (LBH) CSB-YP716190PYX
CSB-EP716190PYX
CSB-BP716190PYX
CSB-MP716190PYX
CSB-EP716190PYX-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Pongo abelii ATP synthase subunit O, mitochondrial (ATP5O) CSB-YP716191PYX
CSB-EP716191PYX
CSB-BP716191PYX
CSB-MP716191PYX
CSB-EP716191PYX-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Pongo abelii Amyloid beta A4 precursor protein-binding family A member 2 (APBA2), partial CSB-YP716192PYX
CSB-EP716192PYX
CSB-BP716192PYX
CSB-MP716192PYX
CSB-EP716192PYX-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Pongo abelii Testican-3 (SPOCK3) CSB-YP716193PYX
CSB-EP716193PYX
CSB-BP716193PYX
CSB-MP716193PYX
CSB-EP716193PYX-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Pongo abelii Glycoprotein endo-alpha-1,2-mannosidase (MANEA), partial CSB-YP716194PYX
CSB-EP716194PYX
CSB-BP716194PYX
CSB-MP716194PYX
CSB-EP716194PYX-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Pongo abelii F-box only protein 42 (FBXO42), partial CSB-YP716195PYX
CSB-EP716195PYX
CSB-BP716195PYX
CSB-MP716195PYX
CSB-EP716195PYX-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Pongo abelii Magnesium transporter NIPA3 (NIPAL1), partial CSB-YP716196PYX
CSB-EP716196PYX
CSB-BP716196PYX
CSB-MP716196PYX
CSB-EP716196PYX-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Pongo abelii Mitochondrial import inner membrane translocase subunit Tim23 (TIMM23), partial CSB-YP716197PYX1
CSB-EP716197PYX1
CSB-BP716197PYX1
CSB-MP716197PYX1
CSB-EP716197PYX1-B
20μg/100μg/1mg(1mg*1 or 500ug*2)

有用資源

什么是重組蛋白?

重組蛋白是一種可操縱的蛋白質(zhì)形式,可以通過多種方式產(chǎn)生大量蛋白質(zhì)、修改基因序列和制造有用的商業(yè)產(chǎn)品。重組蛋白的技術(shù)資源在重組蛋白的開發(fā)過程中,除了表達(dá)系統(tǒng)之外,還面臨著一系列令人困惑的選擇,如表達(dá)載體的選擇、表達(dá)蛋白的長度(全長或部分)、是否帶標(biāo)簽等。在生產(chǎn)重組蛋白時(shí),你必須做出很多決定。如果你選擇的明智,你將獲得高質(zhì)量的重組蛋白,后續(xù)的實(shí)驗(yàn)更有可能成功。但是如果你做了錯(cuò)誤的決定,你可能得不到你所需要的重組蛋白或者重組蛋白的質(zhì)量和純度不符合要求。在這里,來自CUSABIO的蛋白表達(dá)工程師根據(jù)他們開發(fā)重組蛋白的經(jīng)驗(yàn)總結(jié)出了幾個(gè)有用的提示,可以幫助你做出明智的決策。

第一條:重組蛋白的生產(chǎn),在這篇文章中,我們旨在闡明重組蛋白的定義以及如何生產(chǎn)重組蛋白。

第二條:如何選擇合適的表達(dá)載體?

表達(dá)載體是一種DNA分子,它攜帶特定的基因進(jìn)入宿主細(xì)胞,并利用細(xì)胞的蛋白質(zhì)合成機(jī)制來產(chǎn)生由該基因編碼的蛋白質(zhì)。表達(dá)載體可使外源基因在宿主細(xì)胞中高效表達(dá),經(jīng)過多年的發(fā)展,表達(dá)載體已成為一種成熟而受歡迎的生物技術(shù)。在重組蛋白生產(chǎn)過程中是一種基本成分。正如標(biāo)題所示,本文主要總結(jié)了幾個(gè)有用的技巧來選擇合適的表達(dá)載體。

第三條:如何表達(dá)具有生物活性的蛋白質(zhì)?

根據(jù)重組蛋白的不同應(yīng)用,對其生物活性有不同的要求。但是我們?nèi)绾未_保蛋白質(zhì)的產(chǎn)生具有生物活性呢?本文將圍繞這個(gè)主題,并提供一些解決方案。除了以上文章,我們還收集了一些重組蛋白的常見問題。您可以單擊以下鏈接查看。http://m.bdspa.cn/technology-91.html。此外,我們還為我們的客戶提供重組蛋白表達(dá)服務(wù),您可以點(diǎn)擊這里獲取更多信息。注:如果您對CUSABIO的蛋白質(zhì)有任何疑問,涉及到蛋白質(zhì)的價(jià)格、交貨、質(zhì)量等,您可以點(diǎn)擊橙色按鈕為我們在線留言。

引用資料

Recombinant Severe acute respiratory syndrome coronavirus 2 RNA-dependent RNA polymerase(NSP12) cited in "SARS-CoV-2 hijacks cellular kinase CDK2 to promote viral RNA synthesis". Signal transduction and targeted therapy, 2023

Recombinant Mouse Mixed lineage kinase domain-like protein(Mlkl) cited in "OASL phase condensation induces amyloid-like fibrillation of RIPK3 to promote virus-induced necroptosis". Nature cell biology, 2023

Recombinant Mouse Proto-oncogene c-Fos(Fos) cited in "Dihydroartemisinin imposes positive and negative regulation on Treg and plasma cells via direct interaction and activation of c-Fos". Communications biology, 2023

Recombinant Human Keratin, type I cytoskeletal 18(KRT18) cited in "Calcitonin gene-related peptide ameliorates sepsis-induced intestinal injury by suppressing NLRP3 inflammasome activation". International immunopharmacology, 2023

Recombinant Human Protein Wnt-5a (WNT5A) cited in "ATBF1 is a potential diagnostic marker of histological grade and functions via WNT5A in breast cancer". BMC Cancer, 2022

Read More >>



×